Hemostatic effects of salsalate in normal subjects and patients with hemophilia A.
Salsalate in a non-acetylated salicylate with activity as an antirheumatic agent. The hemostatic effects of this agent were studied in twelve healthy subjects and nine patients with hemophilia A. Healthy subjects showed no change in bleeding time, platelet aggregation response to adenosine diphosphate (ADP) or collagen, or adenosine triphosphate (ATP) release in response to arachidonic acid as measured in an impedance whole blood lumi-aggregometer. The patients with hemophilia A showed no bleeding time prolongation nor an effect on ADP or collagen induced platelet aggregation in platelet rich plasma. It is concluded that this agent may be useful in the treatment of arthritis in patients with hereditary coagulation disorders.
Sweeney
J D
JD
Hemophilia Center of Western New York, Buffalo.
Hoernig
L A
LA
D001168:Arthritis / Q000188:drug therapy / Q000209:etiology; D001777:Blood Coagulation / Q000187:drug effects; D006467:Hemophilia A / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D012459:Salicylates / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
D012459:Salicylates; C014182:salicylsalicylic acid